Genomic Health Downgraded by Credit Suisse to Neutral (GHDX)
Genomic Health (NASDAQ:GHDX) was downgraded by stock analysts at Credit Suisse from an “outperform” rating to a “neutral” rating in a report issued on Friday, TheFlyOnTheWall.com reports.
Genomic Health (NASDAQ:GHDX) opened at 26.52 on Friday. Genomic Health has a 1-year low of $25.50 and a 1-year high of $38.99. The stock has a 50-day moving average of $29.95 and a 200-day moving average of $31.91. The company’s market cap is $815.2 million.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, February 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.27. The company had revenue of $68.80 million for the quarter, compared to the consensus estimate of $69.20 million. During the same quarter in the previous year, the company posted $0.06 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. On average, analysts predict that Genomic Health will post $-0.35 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on GHDX. Analysts at Bank of America Corp. downgraded shares of Genomic Health to an “underperform” rating in a research note to investors on Wednesday. They now have a $28.00 price target on the stock, down previously from $30.00. Separately, analysts at JMP Securities cut their price target on shares of Genomic Health from $38.00 to $34.00 in a research note to investors on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Genomic Health from $33.00 to $28.00 in a research note to investors on Wednesday. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $31.80.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.